Date: 2017-03-30
Type of information: Nomination
Compound: member of the strategic and scientific advisory boards
Company: Sarepta Therapeutics (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On March 30, 2017, Sarepta Therapeutics announced the addition of Kenneth Fischbeck and Matthew Wood to the Company’s Strategic and Scientific Advisory Board. Dr. Fischbeck and Dr. Wood join Dr. Beverly Davidson and Dr. Louis Kunkel, who were appointed to the board at the time of its formation in 2015.
- Kenneth Fischbeck, M.D., received A.B. and A.M. degrees from Harvard University and a M.D. degree from Johns Hopkins. After a medical internship at Case Western Reserve University and a neurology residency at the University of California in San Francisco, he did postdoctoral research on muscular dystrophy at the University of Pennsylvania. In 1982, he joined the faculty in the Neurology Department at the University of Pennsylvania Medical School. In 1998, he joined the National Institute of Neurological Disorders and Stroke (NINDS) as Chief of the Neurogenetics Branch. He received the Cotzias Award from the American Academy of Neurology and the Jacoby Award from the American Neurological Association, and he was elected to the Institute of Medicine. His research group is identifying the causes and studying the mechanisms of hereditary neurological and neuromuscular diseases with the goal of developing effective treatment for these disorders.
- Matthew Wood, M.D., Ph.D., is a Professor of Neuroscience and Deputy Head of the Medical Sciences Division at the University of Oxford and directs the Laboratory of RNA biology and Neuromuscular Disease. Dr. Wood is a leading pioneer in the field of oligonucleotide therapies and co-leads the International MDEX Consortium, a major international translational medicine collaboration to develop oligonucleotide treatments for DMD and related neuromuscular conditions, with Dr. Francesco Muntoni of University College London. Sarepta’s Exondys 51 was the first oligonucleotide worked on by this Consortium.
- Dr. Wood is an executive member of the global alliance TREAT-NMD. He serves as a Director of several organizations, including the Oxford MDUK Centre for Translational Neuromuscular Science, the University of Oxford’s technology transfer organization, Oxford University Innovation, and Evox Therapeutics, a company he founded based on his work with exosomes. He currently serves as the Deputy Head of the Medical Sciences Division of the University of Oxford, and holds a Director role on the Board of MedCity.
Financial terms:
Latest news:
Is general: Yes
